Prolonged response of relapsed high grade serous ovarian carcinoma to the oral angiokinase inhibitor nintedanib in a patient with a germline BRCA1 mutation.
- Abstract:
- ► Nintedanib is an anti-angiogenic agent that has demonstrated activity in relapsed ovarian cancer. ► Our patient had prolonged response to nintedanib, allowing her to have potentially curative surgery 6 years after her diagnosis. ► The relationship between angiogenesis and BRCA mutation is worth exploring in ovarian cancer.
- Authors:
- HH Wong, C Parkinson, JA Ledermann, JD Brenton, M Merger, A Shaw, A Patterson, M Shafi, HM Earl
- Journal:
- Gynecol Oncol Case Rep
- Citation info:
- 3:7-10
- Publication date:
- 1st Aug 2012
- Full text
- DOI